Medical Advocates

Kaletra Library Service 
 Conference Abstracts and Posters

Glasgow, Scotland, UK





 

• POSTER
  An open-label multi-centre pilot study evaluating the pharmacokinetics of co-administered lopinavir and nevirapine
  in HIV-infected adults. The NRTI-sparing study.
  Else L, Mahungu T, Cuthbertson Z, et al 
• POSTER
  A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir and nevirapine in
  HIV-1 infected adults. The NRTI-sparing Study.
  Mahungu TW, Else LJ, Cuthbertson ZL, et al 
• POSTER
  Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir:
  Data from the TAIL study.
  Dickinson L, Boffito M, Else L 
• A WEEK IN REVIEW FEATURED REPORT
  POSTER
  Metabolic Evaluation of Study M05-730 through Week (Wk) 48: Phase 3, Randomized, Open-Label
  Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered
  with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naïve (ARV) HIV-1Infected Subjects
  BA da Silva, Y-L Chiu ,J Li, et al
  PDF Poster
• POSTER
  Adherence with Lopinavir/ritonavir (LPV/r) Tablet and Soft-Gel Capsule (SGC)-Based Antiretroviral
  Regimens and Predictors of Early Treatment Compliance
  R Rode , T Marsh, C Naylor, et al
  PDF Poster
• POSTER
  Population Pharmacokinetic/Pharmacodynamic Analyses of Lopinavir and Ritonavir in Subjects
  Receiving the Tablet Formulation
  C Klein, J Ng, YL Chiu, et al 
  PDF Poster
• To overdose or underdose? The question of Kaletra in children in the UK/Irish Collaborative HIV
  Paediatric Study (CHIPS)
  AS Walker, KL Boyd, K Doerholt, et al
  PDF Abstract
• Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules
  in African patients
  C Kityo, AS Walker, F Lutwana, et al
  PDF Abstract
• Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III
  TITAN trial in treatment-experienced patients
  S De Meyer, E Lathouwers, I Dierynck, et al 
  PDF Abstract
• Use of lopinavir/ritonavir in first-line therapy or second-line therapy: 48-week results from the German
  prospective STAR cohort
  C Koegl, A Trein, W Schmidt, et al
  Abstract
• Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior
  different antiretroviral treatments
  B Conway, J DeWet, A Tsang, et al 
  Abstract
• Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on QTcF: results of a thorough
  QT study
  CE Klein, YL Chiu, BA Da Silva, et al 
  Abstract
• A 24-month follow-up of the metabolic profile of Greek HIV (+) population on lopinavir/ritonavir-based regimen:
  the ACA GREC trial
  SM Metallidis, ML Lazanas, PG Gargalianos, et al
  Abstract
• HIV patients' gastrointestinal tolerability and treatment satisfaction after switching from lopinavir/ritonavir
  (LPV/r) SGC to co-formulated LPV/r tablets
  J Borras-Blasco, JD Rosique-Robles, A Belda, et al 
  Abstract
• Adherence with lopinavir/ritonavir (LPV/r) tablet and SoftGel (SGC) capsule based antiretroviral regimens and
  predictors of early treatment compliance
  TJ Podsadecki, RA Rode, C Naylor, et al 
  Abstract
• Re-evaluation of resistance algorithms for lopinavir/ritonavir in the TITAN trial
  V Calvez, AM Hill, AG Marcelin, et al
  Abstract
• Therapeutic drug monitoring of new formulation Kaletra in pregnancy
  V Jackson, LJ Else, SH Khoo, et al
  Abstract
• Safety and efficacy of lopinavir/ritonavir compared to nelfinavir-based HAART during pregnancy
  JM Peña, MI González, JF Pascual-Parejam et al
  Abstract
• Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens
  based on 48-week results from the CASTLE study
  Simpson KN, Rajagopalan R, Dietz B, et al 
  Abstract
• 96 weeks pharmacoeconomic outcome of lopinavir/r monotherapy as maintenance strategy in HIV+ patients with
  suppressed viral load. OK04-PharmECO analysis
  Arribas JR, Pulido F, Méndez I, et al
  Abstract
• Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples
  Santos JR, Llibre JM, Pérez-Álvarez N, et al
  Abstract
• Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenz
  Bedimo RJ, Drechsler H, Holodniy M, et al
  Abstract
• KAPITAL2: a study of treatment satisfaction reported by patients on lopinavir/r anchored regimens and
  physicians who provide HIV care
  Casado JL, Griffa L, Cabrero E, et al
  Abstract